What Qure.ai Announced About the qXR-Detect Clearances
Qure.ai said on 26 February 2026 that the FDA granted 510(k) Class II clearance to qXR-Detect, software that finds and sorts chest X-ray findings across six areas: lung, pleura, mediastinum and hila with the heart, bone, hardware, and other findings. The company says the six new indications bring its total to 26 FDA-cleared indications across nine products.
Why the Qure.ai qXR-Detect Clearances Matter to Radiology Buyers
Most radiology AI is bought one finding at a time, so a single cleared product that reports across six areas of the same image can replace several contracts and several integrations. The count is a measure of regulatory paperwork, not of accuracy, and a buyer still has to see the performance data for each finding separately. A tool cleared to detect is also not the same as a tool cleared to triage, so the workflow it slots into matters as much as the list of indications.
Where the Qure.ai Update Comes From
Qure.ai is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.
How We Would Research the Qure.ai qXR-Detect Clearances
The source gives us the starting point. This is how we would build the next layer of research around it.
- We would start with the 510(k) summary for qXR-Detect and read the indications for use area by area.
- Then we would ask Qure.ai for the reader study behind each of the six areas, because a combined number hides the weakest one.
- We would check how the product reports into our own reading workflow, since a detection tool and a triage tool change a radiologist's day in different ways.